MX9705820A - El uso de (s)-oxibutinina y (s)-desetiloxibutinina en la preparacion de composiciones para el tratamiento de incontinencia urinaria, las composiciones obtenidas y el procedimiento para preparar desetiloxibitinina. - Google Patents

El uso de (s)-oxibutinina y (s)-desetiloxibutinina en la preparacion de composiciones para el tratamiento de incontinencia urinaria, las composiciones obtenidas y el procedimiento para preparar desetiloxibitinina.

Info

Publication number
MX9705820A
MX9705820A MX9705820A MX9705820A MX9705820A MX 9705820 A MX9705820 A MX 9705820A MX 9705820 A MX9705820 A MX 9705820A MX 9705820 A MX9705820 A MX 9705820A MX 9705820 A MX9705820 A MX 9705820A
Authority
MX
Mexico
Prior art keywords
desethyloxybutynin
oxybutynin
urinary incontinence
treating urinary
disclosed
Prior art date
Application number
MX9705820A
Other languages
English (en)
Other versions
MXPA97005820A (es
Inventor
Gunnar Aberg
Jonh R Mc Cullough
Yue Fang
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,542 external-priority patent/US5532278A/en
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of MX9705820A publication Critical patent/MX9705820A/es
Publication of MXPA97005820A publication Critical patent/MXPA97005820A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describe el uso de una cantidad terapéuticamente efectiva de un compuesto escogido del grupo que consiste de (5)- oxibutinina y (5)-desetiloxibutinina o una sal farmacéuticamente aceptable de las mismas, substancialmente libre de su enantiomero R, en la preparacion de composiciones para el tratamiento de incontinencia urinaria mientras se evita el riesgo concomitante de efectos adversos, en un ser humano que necesita dicho tratamiento; también se describen composiciones farmacéuticas en forma de tabletas y dispositivos de surtido transdérmicos que comprenden (5)-oxibutinina o (5)-desetiloxibutinina y un vehículo aceptable, así como síntesis de desetiloxibutinina.
MXPA/A/1997/005820A 1995-01-31 1997-07-30 El uso de (s)-oxibutinina y (s)-desetiloxibutinina en la preparacion de composiciones para el tratamiento de incontinencia urinaria, las composiciones obtenidas y el procedimiento para preparar desetiloxibitinina MXPA97005820A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08381542 1995-01-31
US08/381,542 US5532278A (en) 1995-01-31 1995-01-31 Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US08480194 1995-06-07
US08/480,194 US5677346A (en) 1995-01-31 1995-06-07 Treating urinary incontinence using (S)-desethyloxybutynin
PCT/US1996/001053 WO1996023492A1 (en) 1995-01-31 1996-01-25 Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin

Publications (2)

Publication Number Publication Date
MX9705820A true MX9705820A (es) 1997-10-31
MXPA97005820A MXPA97005820A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
JPH11511730A (ja) 1999-10-12
CA2211400C (en) 2007-01-23
WO1996023492A1 (en) 1996-08-08
GR3034974T3 (en) 2001-02-28
HUP9800794A3 (en) 1999-05-28
ATE196252T1 (de) 2000-09-15
CA2211400A1 (en) 1996-08-08
SK283313B6 (sk) 2003-05-02
PL182768B1 (pl) 2002-02-28
CN1179714A (zh) 1998-04-22
CN1151786C (zh) 2004-06-02
BR9607001A (pt) 1997-10-28
NZ303372A (en) 1999-01-28
NO973516D0 (no) 1997-07-30
UA45387C2 (uk) 2002-04-15
FI973163A0 (fi) 1997-07-30
EP0806948A1 (en) 1997-11-19
DE69610290D1 (de) 2000-10-19
DK0806948T3 (da) 2000-12-18
NO973516L (no) 1997-08-07
CZ290093B6 (cs) 2002-05-15
AU706741B2 (en) 1999-06-24
DE69610290T2 (de) 2001-03-29
HK1017986A1 (en) 1999-12-10
AU4966496A (en) 1996-08-21
KR100390271B1 (ko) 2003-10-04
RU2181589C2 (ru) 2002-04-27
ES2150663T3 (es) 2000-12-01
CZ242197A3 (en) 1997-12-17
PL321498A1 (en) 1997-12-08
HUP9800794A2 (hu) 1998-07-28
SK103597A3 (en) 1999-03-12
NO315927B1 (no) 2003-11-17
PT806948E (pt) 2001-02-28
US5677346A (en) 1997-10-14
EP0806948B1 (en) 2000-09-13
FI973163A (fi) 1997-09-30

Similar Documents

Publication Publication Date Title
GR3034974T3 (en) Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin
CA2257121A1 (en) Methods and compositions for treating urinary incontinence using optically pure (s)-oxybutynin
CA2215329A1 (en) Colorectal chemoprotective composition and method for preventing colorectal cancer
DK0867179T3 (da) Sammensætning af L-DOPA-estere
MY129473A (en) 3,3-diarylpropylamines, their use and preparation
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
PL337648A1 (en) (+)-norcisapride useful in case of disorders occurring under mediation of 5-ht3 and 5-ht4
EP1026157A3 (en) Method for the synthesis of huperzine A and analogs thereof and compounds useful therein
WO2003002059A3 (en) Tolterodine metabolites
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
WO1999033454A3 (en) S-procyclidine for treating urinary incontinence
WO1996021670A3 (en) Antifungal fusacandins
WO2000076490A3 (en) Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin
WO1999033453A3 (en) R-procyclidine for treating urinary incontinence
AU1305999A (en) (+)-ephedrine as a sympathomimetic drug
JO1738B1 (en) A new therapeutically active compound
TW218014B (en) A new therapeutically active compound
GB9508482D0 (en) A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product
MX9801192A (es) Nuevos peptidos opioides.
MY110416A (en) Composition for the treatment of schizophrenia.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees